Trazodone and imipramine: comparative effects on canine cardiac conduction

Area of Science:

• Cardiology
• Pharmacology
• Neuroscience

Background:

• Antidepressant medications can have varying effects on cardiac function.
• Tricyclic antidepressants are known to possess cardiotoxic properties.
• Understanding the cardiac safety profile of new antidepressants like trazodone is crucial.

Purpose of the Study:

• To evaluate the cardiac electrophysiological effects of trazodone in a canine model.
• To compare the cardiac effects of trazodone with imipramine, a known cardiotoxic tricyclic antidepressant.

Main Methods:

• Electrocardiograms (EKG) and His bundle electrograms were recorded in anesthetized dogs.
• Intravenous administration of graded doses of trazodone (1-30 mg/kg) and imipramine (0.5-5 mg/kg).
• Analysis of cardiac intervals including His-Purkinje (HV), intraventricular (HS), atrioventricular (PA), PR, and QRS durations.

Main Results:

• Trazodone showed no significant effect on His-Purkinje or intraventricular conduction.
• Imipramine significantly slowed His-Purkinje and intraventricular conduction, prolonging HV and HS intervals.
• Imipramine also slowed atrial conduction (PA interval) and prolonged PR and QRS durations.
• Trazodone did not induce heart block or significant rhythm disturbances.

Conclusions:

• Trazodone appears to have a favorable cardiac electrophysiological profile compared to imipramine.
• Tricyclic antidepressants like imipramine demonstrate significant cardiac conduction slowing effects.
• These findings suggest trazodone may offer a safer cardiac option among antidepressants.